Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors

Lisa Kinget; Oliver Bechter; Kevin Punie; Philip R. Debruyne; Hilde Brems; Paul Clement; Eduard Roussel; Yannick Van Herck; Maarten Albersen; Marcella Baldewijns; Patrick Schöffski; Benoit Beuselinck

doi:10.3390/CURRONCOL28050280

Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors

Lisa Kinget
, Oliver Bechter
, Kevin Punie
, Philip R. Debruyne
, Hilde Brems
, Paul Clement
, Eduard Roussel
, Yannick Van Herck
, Maarten Albersen
, Marcella Baldewijns
, Patrick Schöffski
, Benoit Beuselinck^*

^*Corresponding author for this work

KU Leuven
AZ Groeninge
Anglia Ruskin University

Research output: Contribution to journal › Article › peer-review

Abstract

In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage response (DDR) pathway harbor a higher tumor mutational burden, possibly associated with an increased tumoral neoantigen load. These neoantigens are thought to lead to stronger immune activation and enhanced response to ICPIs. We present a series of seven patients with different malignancies with germline disease-associated variants in DDR genes (BRCA1, BRCA2, CHEK2) responding favorably to ICPIs.

Original language	English
Pages (from-to)	3227-3239
Number of pages	13
Journal	Current Oncology
Volume	28
Issue number	5
DOIs	https://doi.org/10.3390/CURRONCOL28050280
Publication status	Published - Oct 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Oncology

Keywords

BRCA1
BRCA2
CHEK2
DNA damage response
Immune checkpoint inhibitors

Access to Document

10.3390/CURRONCOL28050280

Cite this

Kinget, L., Bechter, O., Punie, K., Debruyne, P. R., Brems, H., Clement, P., Roussel, E., Van Herck, Y., Albersen, M., Baldewijns, M., Schöffski, P., & Beuselinck, B. (2021). Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors. Current Oncology, 28(5), 3227-3239. https://doi.org/10.3390/CURRONCOL28050280

@article{41dcd4be77f34cde9cd79a9b06286e90,

title = "Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors",

abstract = "In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage response (DDR) pathway harbor a higher tumor mutational burden, possibly associated with an increased tumoral neoantigen load. These neoantigens are thought to lead to stronger immune activation and enhanced response to ICPIs. We present a series of seven patients with different malignancies with germline disease-associated variants in DDR genes (BRCA1, BRCA2, CHEK2) responding favorably to ICPIs.",

keywords = "BRCA1, BRCA2, CHEK2, DNA damage response, Immune checkpoint inhibitors",

author = "Lisa Kinget and Oliver Bechter and Kevin Punie and Debruyne, \{Philip R.\} and Hilde Brems and Paul Clement and Eduard Roussel and \{Van Herck\}, Yannick and Maarten Albersen and Marcella Baldewijns and Patrick Sch{\"o}ffski and Benoit Beuselinck",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).",

year = "2021",

month = oct,

doi = "10.3390/CURRONCOL28050280",

language = "English",

volume = "28",

pages = "3227--3239",

journal = "Current Oncology",

issn = "1718-7729",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

Kinget, L, Bechter, O, Punie, K, Debruyne, PR, Brems, H, Clement, P, Roussel, E, Van Herck, Y, Albersen, M, Baldewijns, M, Schöffski, P & Beuselinck, B 2021, 'Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors', Current Oncology, vol. 28, no. 5, pp. 3227-3239. https://doi.org/10.3390/CURRONCOL28050280

TY - JOUR

T1 - Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors

AU - Kinget, Lisa

AU - Bechter, Oliver

AU - Punie, Kevin

AU - Debruyne, Philip R.

AU - Brems, Hilde

AU - Clement, Paul

AU - Roussel, Eduard

AU - Van Herck, Yannick

AU - Albersen, Maarten

AU - Baldewijns, Marcella

AU - Schöffski, Patrick

AU - Beuselinck, Benoit

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

PY - 2021/10

Y1 - 2021/10

N2 - In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage response (DDR) pathway harbor a higher tumor mutational burden, possibly associated with an increased tumoral neoantigen load. These neoantigens are thought to lead to stronger immune activation and enhanced response to ICPIs. We present a series of seven patients with different malignancies with germline disease-associated variants in DDR genes (BRCA1, BRCA2, CHEK2) responding favorably to ICPIs.

AB - In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage response (DDR) pathway harbor a higher tumor mutational burden, possibly associated with an increased tumoral neoantigen load. These neoantigens are thought to lead to stronger immune activation and enhanced response to ICPIs. We present a series of seven patients with different malignancies with germline disease-associated variants in DDR genes (BRCA1, BRCA2, CHEK2) responding favorably to ICPIs.

KW - BRCA1

KW - BRCA2

KW - CHEK2

KW - DNA damage response

KW - Immune checkpoint inhibitors

UR - https://www.scopus.com/pages/publications/85115347602

U2 - 10.3390/CURRONCOL28050280

DO - 10.3390/CURRONCOL28050280

M3 - Article

C2 - 34449592

AN - SCOPUS:85115347602

SN - 1718-7729

VL - 28

SP - 3227

EP - 3239

JO - Current Oncology

JF - Current Oncology

IS - 5

ER -

Multitumor case series of germline brca1, brca2 and chek2-mutated patients responding favorably on immune checkpoint inhibitors

Abstract

UN SDGs

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this